Moonwalk Biosciences is a biotechnology company based in South San Francisco and San Diego developing first-in-class, adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases. Its platform pairs human genetics, epigenomics and multi-omics discovery with proprietary tissue-targeting chemistry, exclusively licensed from Suzhou Siran Biotechnology, to deliver siRNA directly to fat tissue while minimizing effects on other tissues — targeting durable weight loss, preserved lean mass and infrequent dosing. Lead candidate MW101, an siRNA obesity therapy, is slated to enter first-in-human clinical studies in late 2027; the company is led by co-founder and CEO Alex Aravanis and launched with a $57 million financing.
1
Round
1
Industry
4
Tags
Sep 8, 2026
Latest raise
Funding activity · 1 round
Sep 8, 2026
$70M
Series B
Led by YK Bioventures
Moonwalk Biosciences Closes $70M Series B Moonwalk Biosciences, a biotechnology company based in South San Francisco and San Diego, has raised a $70 million Se…
Read articlePricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
